Sanofi, Cellectis team up to pair Lemtrada with allogeneic CAR-Ts; Bristol Myers joins Evotec's drive to advance UK science

Sanofi is partnering up with Cellectis on their allogeneic CAR-Ts.

Cellectis struck a deal to use the French pharma’s drug alemtuzumab (Lemtrada, an MS agent) as part of its lymphodepletion regimen — used to sideline host immune cells and improve CAR-T cell expansion and persistence.